发明申请
US20090258892A1 FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
审中-公开
熔化的吡唑衍生物及其代谢相关疾病的治疗方法
- 专利标题: FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF
- 专利标题(中): 熔化的吡唑衍生物及其代谢相关疾病的治疗方法
-
申请号: US12433704申请日: 2009-04-30
-
公开(公告)号: US20090258892A1公开(公告)日: 2009-10-15
- 发明人: P. Douglas Boatman , Thomas O. Schrader , Graeme Semple , Philip J. Skinner , Jae-Kyu Jung
- 申请人: P. Douglas Boatman , Thomas O. Schrader , Graeme Semple , Philip J. Skinner , Jae-Kyu Jung
- 申请人地址: US CA San Diego
- 专利权人: ARENA PHARMACEUTICALS, INC.
- 当前专利权人: ARENA PHARMACEUTICALS, INC.
- 当前专利权人地址: US CA San Diego
- 主分类号: A61K31/437
- IPC分类号: A61K31/437 ; C07D231/54 ; C07D403/04 ; A61K31/416 ; A61K31/41 ; A61K31/40
摘要:
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.